Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has shared an update.
Qiagen has disclosed a voting rights announcement after the Dutch financial regulator AFM notified the company of a substantial shareholding position held by BlackRock, Inc. and its affiliates as of March 10, 2026. The filing shows that BlackRock’s aggregate interest in Qiagen amounts to 10.61% of the company’s capital and 11.76% of voting rights through a mix of ordinary shares and contracts for difference, all held indirectly via various BlackRock entities.
The structure of the holdings spans multiple jurisdictions and instruments, combining real and potential positions, including physical and cash-settled exposures. Qiagen emphasized that it is not responsible for the accuracy of the details, which are taken from the AFM’s public register, but the disclosure underscores the significant role of a major global asset manager in Qiagen’s shareholder base and may be relevant for investors tracking ownership concentration and governance influence.
The most recent analyst rating on (QGEN) stock is a Hold with a $47.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies for molecular diagnostics, applied testing, academic research and pharmaceutical development. Its shares are listed in Frankfurt and on several other European exchanges, as well as on the New York Stock Exchange and Swiss markets, giving it broad international investor exposure.
Average Trading Volume: 2,335,786
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.5B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.